189 related articles for article (PubMed ID: 16519546)
21. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
22. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Kaufmann M; Rody A
J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
[TBL] [Abstract][Full Text] [Related]
23. [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].
Gamboa O; Díaz S; Chicaíza L; García M
Biomedica; 2010; 30(1):46-55. PubMed ID: 20890549
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Okubo I; Kondo M; Toi M; Ochiai T; Miki S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
[TBL] [Abstract][Full Text] [Related]
25. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Dranitsaris G; Verma S; Trudeau M
Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
[TBL] [Abstract][Full Text] [Related]
26. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
27. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
28. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
29. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
[TBL] [Abstract][Full Text] [Related]
31. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
32. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Scott LJ; Keam SJ
Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.
Karnon J; Brown J;
Pharmacoeconomics; 2002; 20(2):119-37. PubMed ID: 11888364
[TBL] [Abstract][Full Text] [Related]
35. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
[TBL] [Abstract][Full Text] [Related]
37. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Moeremans K; Annemans L
Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
[TBL] [Abstract][Full Text] [Related]
39. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Younis T; Rayson D; Dewar R; Skedgel C
Ann Oncol; 2007 Feb; 18(2):293-8. PubMed ID: 17095569
[TBL] [Abstract][Full Text] [Related]
40. Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
Goss PE
Semin Oncol; 2004 Dec; 31(6 Suppl 12):15-22. PubMed ID: 15719597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]